Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Controlled, Randomized, Parallel , Multi-Centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA [vitamin K antagonist] Therapy.

Next Previous
Trial Profile

A Controlled, Randomized, Parallel , Multi-Centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA [vitamin K antagonist] Therapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 0837 (Primary) ; Aspirin; Clopidogrel
  • Indications Embolism; Ischaemic stroke
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 14 Nov 2009 Results were presented at the 82nd Annual Scientific Sessions of the American Heart Association.
  • 02 Jul 2008 The expected completion date for this trial has been extended from May 2008 to Dec 2008 as reported by ClinicalTrials.gov.
  • 11 May 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top